Effect of Resistant Starch on the Gut Microbiota and Its Metabolites in Patients with Coronary Artery Disease

Naofumi Yoshida¹, Kengo Sasaki², Daisuke Sasaki², Tomoya Yamashita¹, Hajime Fukuda³, Tomohiro Hayashi¹, Tokiko Tabata¹, Ro Osawa⁴,⁵, Ken-ichi Hirata¹ and Akihiko Kondo²,⁶

Naofumi Yoshida and Kengo Sasaki contributed equally to this work.

¹Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
²Graduate School of Science, Technology and Innovation, Kobe University, Kobe, Japan
³Nippon Starch Chemical Co., Ltd., Osaka, Japan
⁴Research Center for Food Safety and Security, Graduate School of Agricultural Science, Kobe University, Kobe, Japan
⁵Department of Bioresource Science, Graduate School of Agricultural Science, Kobe University, Kobe, Japan
⁶RIKEN Center for Sustainable Resource Science, Yokohama, Japan

Aim: Bacteroides vulgatus and B. dorei have a protective effect against atherosclerosis, suggesting that expansion of these species in the gut microbiota could help patients with coronary artery disease (CAD). This study aimed to investigate the effect of resistant starch (RS) on the gut microbiota and its metabolites in fecal sample cultures from patients with CAD and individuals without CAD, using a single-batch fermentation system.

Methods: Fecal samples from 11 patients with CAD and 10 individuals without CAD were fermented for 30 h with or without RS in the Kobe University Human Intestinal Microbiota Model (KUHIMM). Gut microbiota and the abundance of B. vulgatus and B. dorei were analyzed using 16S ribosomal ribonucleic acid (rRNA) gene sequencing and the quantitative polymerase chain reaction. Short-chain fatty acids were analyzed using high-performance liquid chromatography.

Results: Gut microbial analysis showed significantly lower levels of B. vulgatus and B. dorei in the original fecal samples from patients with CAD, which was simulated after 30 h of fermentation in the KUHIMM. Although RS significantly increased the absolute numbers of B. vulgatus and B. dorei, and butyrate levels in CAD fecal sample cultures, the numbers varied among each patient.

Conclusions: The effect of RS on gut microbiota and its metabolites in the KUHIMM varied between CAD and non-CAD fecal sample cultures. The KUHIMM may be useful for preclinical evaluations of the effects of RS on the gut microbiota and its metabolites.

Key words: Coronary artery disease, Gut microbiota, Resistant starch, Bacteroides
results, individuals with low levels of bacteria of the genus *Bacteroides* have a higher incidence of atherosclerosis\(^{10, 11}\). In addition, we have recently reported that *B. vulgatus* and *B. dorei* protect against atherosclerosis by ameliorating endotoxemia\(^{12}\). Because these findings may lead to the development of novel approaches for the prevention and treatment of CAD by modulating the components of the gut microbiota, recent studies have focused on non-invasive interventions that could modulate gut microbiota\(^{5, 13, 14}\).

Each gut microbial profile depends on age, sex, local diet or lifestyle, drugs, and other many factors. These factors may relate to the progression of CAD via modulation of gut microbiota. The findings from many clinical trials and animal studies have shown that diet plays a central role in shaping the gut microbiota\(^{15, 16}\). Undigested dietary fiber, in particular, alters the microbial ecosystem of the gut and its composition, because the gut microbiota uses dietary fiber as a primary energy source\(^{17, 18}\). The findings from several human studies have shown higher *Bacteroidetes*-to-*Firmicutes* ratios and higher *Bacteroides* levels in people who consume high-fiber diets\(^{19, 20}\). Although the findings from large epidemiological studies have consistently shown that intake of dietary fiber can prevent CAD in healthy subjects\(^{21-23}\), the beneficial effects of altering the gut microbiota in patients with CAD remain unclear\(^{24}\).

SCFAs, primarily acetate, propionate, and butyrate, are the end products of dietary fiber fermentation generated by gut microbiota, and these end products act as signaling molecules to regulate the metabolism and inflammatory responses of the host\(^{25-27}\).

**Aim**

This study aimed to determine whether undigested dietary fiber could alter the gut microbiota from patients with CAD to achieve a symbiotic state. We used a single-batch anaerobic fermentation system, namely, the Kobe University Human Intestinal Microbiota Model (KUHIMM), to explore our hypothesis\(^{28-30}\), because ethical considerations constrain human interventional clinical trials. The KUHIMM can simulate the human gut microbiota metagenomically and metabolically, and it facilitates evaluations of the effect of dietary fiber on the gut microbiota before clinical trials. Because undigested dietary fiber in the form of resistant starch (RS) increases the abundance of *Bacteroides* spp. in mice\(^ {31}\), we fermented feces obtained from CAD patients with RS in the KUHIMM. We also fermented feces obtained from non-CAD control individuals with coronary risk factors, including hypertension, diabetes, and dyslipidemia to compare the effects of RS on the gut microbiota between CAD patients and non-CAD control individuals.

**Methods**

### Study Participants

Eleven patients with CAD comprised the study group and 10 individuals without CAD who had coronary risk factors comprised the non-CAD control group. Study participants were recruited at Kobe University Hospital between February 2017 and December 2017. Patients with heart failure; renal disease, which was defined as a serum creatinine concentration >2.0 mg/dL; hepatic disease; malignancies; or concomitant inflammatory conditions were excluded from the study. Patients who were treated with antibiotics during the 4 weeks before the study commenced were also excluded from our study. Written informed consent was obtained from all participants, and the study was conducted according to the principles of the Declaration of Helsinki. This study was approved by Kobe University's Ethics Committee (Approval no. 160191), and it was registered with the UMIN Clinical Trials Registry (Trial registration no. UMIN000024555).

### Blood Sampling

Blood samples collected after an overnight fast were tested to determine the levels of aspartate aminotransferase, alanine aminotransferase, \(\gamma\)-glutamyl transpeptidase, C-reactive protein, blood urea nitrogen, creatinine, glycated hemoglobin, high-density lipoprotein, low-density lipoprotein (LDL), total cholesterol, triglyceride, and brain natriuretic peptide.

### Fecal Samples and Culture With Resistant Starch

We used the KUHIMM, which is a small-scale multichannel fermenter (Bio Jr.8; ABLE, Tokyo, Japan) that comprises eight parallel and independent anaerobic culture vessels (Supplementary Fig. 1)\(^{28-30}\). A maximum of eight independent experiments can be performed, which uses all of the vessels. Each vessel contains 100 mL of Gifu anaerobic medium (Nissui Pharmaceutical Co., Ltd, Tokyo, Japan) at pH 6.5. The medium was maintained at 37°C and was stirred regularly at 300 rpm. Anaerobiosis was maintained by the continuous in-flow (15 mL/min) of a filtered gas mixture comprising 80% \(\mathrm{N}_2\) and 20% \(\mathrm{CO}_2\).

Fecal samples were collected during the time that the participants were hospitalized and thus consuming a hospital diet for more than 1 day. Hospital diet contains approximately 12 g/day of dietary fiber. Each fecal sample stored in an anaerobic culture swab trans-
port device (BBL™ CultureSwab™; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) was used within 24 h. The fecal samples were suspended in 2 mL of 0.1 M phosphate buffer at pH 6.5, which comprised a 2:1 mixture of NaH2PO4 and 0.1 M Na2HPO4 supplemented with 1% L-ascorbic acid (Wako Pure Chemical Industries, Osaka, Japan). One vessel was inoculated with 100 µL of a fecal suspension only (culture group). Immediately after the fecal inoculation, 0.5% RS (FIBOSE®; Nippon Starch Chemical Co., Ltd., Osaka, Japan) was added to some of the vessels.

**Microbial Deoxyribonucleic Acid Extraction**

Microbial genomic deoxyribonucleic acid (DNA) was extracted from fecal sample suspensions and the culture broths from the KUHIMM at 30 h, as described previously30. The purified DNA was eluted into Tris-EDTA buffer, comprising 10 mM Tris-HCL and 1.0 mM EDTA, and was stored at −80°C until required.

**Library Generation**

Bacterial 16s ribosomal ribonucleic acid (RNA) genes from the V3–V4 region were amplified using genomic DNA as the template and the primers S-D-Bact-0341-b-S-17 (5'-CCTACGGGNGGCWG-CAG-3') and S-D-Bact-0785-a-A-21 (5'-GACTACHVGGGTATCTAATCC-3')32, as described previously30. Index primers (Nextera XT Index Kit; Illumina, Inc., San Diego, CA, USA) overhanging the gene-specific sequences. The polymerase chain reaction (PCR) preparation and assays were performed according to the manufacturer’s instructions. The amplicons were purified using AMPure XP DNA purification beads (Beckman Coulter, Brea, CA, USA), and they were eluted in 25 µL of 10 mM Tris buffer (pH 8.5). The purified amplicons were quantified using an Agilent Bioanalyzer 2100 with DNA 1000 chips (Agilent Technologies, Santa Clara, CA, USA) and Qubit 2.0 (Thermo Fisher Inc., Waltham, MA, USA), and they were pooled at equimolar concentrations (5 nM). The 16S ribosomal RNA genes and an internal control (PhiX control v3; Illumina) were subjected to 600 cycles of paired-end sequencing using a MiSeq® reagent kit (Illumina, Inc.) and an Miseq® reagent kit v3 (Illumina, Inc.). The PhiX sequences were removed, and paired-end reads with Q scores ≥ 20 were joined using MacQIIME software, version 1.9.1 (Werner Lab, Cortland, NY, USA)33. The UCLUST algorithm34 was used to cluster the filtered sequences into operational taxonomic units (OTUs) based on a ≥ 97% similarity threshold. The chimeric sequences were checked and removed from the library using ChimeraSlayer35. Representative sequences from each OTU were taxonomically classified using the GreenGenes taxonomic database and the Ribosomal Database Project Classifier36.

**Quantitative Real-Time Polymerase Chain Reaction**

Quantitative real-time PCR analyses were performed using SYBER Premix Ex Taq (#RR820; Takara Bio, Inc., Shiga, Japan) and a LightCycler® 96 System (#05815916001; Roche Applied Science, Mannheim, Germany) according to the manufacturers’ instructions. We used PCR primers to detect B. vulgatus and B. dorei, as described previously37.

**Short-Chain Fatty Acid Analysis**

The levels of acetate, propionate, and butyrate were measured using a high-performance liquid chromatograph (Shimadzu Corporation, Kyoto, Japan) equipped with an Aminex HPX-87H column (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and an RID-10A refractive index detector (Shimadzu Corporation) at 65°C. The mobile phase comprised 5 mM H2SO4 at a flow rate of 0.6 mL/min.

**Statistical Analyses**

The statistical analyses were performed using JMP software, version 14 (SAS Institute, Cary, NC, USA), R version 3.1.0 (The R Foundation for Statistical Computing, Vienna, Austria; http://cran.r-project.org), MacQIIME (Werner Lab), and GraphPad Prism software, version 7.0 (GraphPad Software; La Jolla, CA, USA). The Shapiro–Wilk test was used to determine the normality of the data. The results are expressed as the means and the standard deviations for the normally distributed data, and as the medians and the interquartile ranges (25th–75th percentiles) for the non-normally distributed data. The differences in the continuous parameters between groups of unpaired data were analyzed using the two-tailed Student’s t-test for the normally distributed data or the Mann–Whitney U-test for the non-normally distributed data. Comparisons of samples from the same patients were performed using the paired t-test or the Wilcoxon signed-rank test for matched pairs. The categorical variables were compared using Fisher exact test or the chi-squared test. The clustering of the data from the patients with CAD (n=11) and from the individuals who did not have CAD (n=10) was performed at the genus level, as previously described12. The Shannon–Wiener index and the Simpson index were calculated using MacQIIME (Werner Lab). The principal component analysis was conducted using JMP software (SAS Institute). All statistical analyses

---

**Effect of RS on Gut Microbiota**
Results

Participant Characteristics at Baseline and Differences in the Profiles of the Gut Microbes

Table 1 presents the baseline characteristics of the study participants. Patients with CAD were significantly older than the non-CAD control individuals. The groups did not differ in terms of sex, the body mass index, and smoking history, and the groups were comparable in terms of the laboratory data, with the exceptions noted.

| Variables                  | Non-CAD controls (n = 10) | CAD (n = 11) |
|----------------------------|---------------------------|--------------|
| Age (years)                | 63.4 ± 6.3                | 73.1 ± 10.4* |
| Sex, male (%)              | 7 (70)                    | 10 (91)      |
| BMI (kg/m²)                | 24.3 ± 4.2                | 24.0 ± 3.1   |
| Laboratory data            |                           |              |
| AST (U/L)                  | 27.1 ± 11.7               | 24.0 ± 4.3   |
| ALT (U/L)                  | 23.6 ± 12.5               | 22.5 ± 8.7   |
| γ-GTP (U/L)                | 49.3 ± 38.2               | 30.7 ± 18.5  |
| BUN (mg/dL)                | 15.3 ± 4.2                | 18.8 ± 3.9   |
| Creatinine (mg/dL)         | 0.9 ± 0.2                 | 0.9 ± 0.14   |
| T-Cho (mg/dL)              | 199.7 ± 21.7              | 157.9 ± 39.8*|
| HDL-C (mg/dL)              | 55.7 ± 15.1               | 48.8 ± 15.1  |
| LDL-C (mg/dL)              | 117.6 ± 17.5              | 82.9 ± 23.0**|
| TG (mg/dL)                 | 181.8 ± 108.1             | 171.4 ± 201.7|
| HbA1c (NGSP%)              | 6.0 ± 0.7                 | 6.6 ± 1.1    |
| CRP (mg/dL)                | 0.05 ± 0.06               | 0.15 ± 0.16  |
| BNP (pg/mL)                | 40.1 ± 38.2               | 45.9 ± 25.4  |
| History of smoking, n (%)  | 6 (60)                    | 4 (36)       |
| Current smoker, n (%)      | 3 (30)                    | 2 (18)       |
| Past history, n (%)        |                           |              |
| Diabetes Mellitus          | 2 (20)                    | 5 (45)       |
| Dyslipidemia               | 5 (50)                    | 11 (100)*    |
| Hypertension               | 5 (50)                    | 9 (82)       |
| Medications, n (%)         |                           |              |
| ACE-I/ARB                  | 4 (40)                    | 6 (55)       |
| Anticoagulant or Antiplatelet | 6 (60)               | 10 (91)    |
| β-blocker                  | 2 (20)                    | 2 (18)       |
| Calcium channel blocker    | 6 (60)                    | 4 (36)       |
| Metformin                  | 0 (0)                     | 2 (18)       |
| α-glucosidase inhibitor    | 0 (0)                     | 1 (9)        |
| PPI/H2 blocker             | 6 (60)                    | 10 (91)      |
| Statin                     | 4 (40)                    | 11 (100)**   |

Data are shown as mean ± standard deviation, or counts (%). The averages of continuous variables were compared using either the two-tailed student’s t test. Fisher’s exact test were used to compare the proportions of categorical variables between groups. A two-sided value of $p < 0.05$ was considered statistically significant. ACEI, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CAD, coronary artery disease; CRP, C-reactive protein; H2 blocker, histamine H2-receptor antagonist; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NGSP, National Glycohemoglobin Standardization Program; PPI, proton pump inhibitor; γ-GTP, γ-glutamyl transpeptidase; T-Cho, total cholesterol; TG, triglycerides *$p < 0.05$, **$p < 0.01$. 

were two-sided, and a value of $p < 0.05$ was considered statistically significant.

Data Availability

All data from this study are available from the corresponding author following reasonable requests. The sequencing data have been deposited into the DNA databank of the Japan BioProject database with links to the BioProject accession number PRJDB7456.
The V3–V4 regions of the bacterial 16S ribosomal ribonucleic acids in fecal samples from 10 non-CAD control subjects and 11 CAD patients were sequenced. (A) The participants were categorized into three clusters based on the abundance at the genus level in the gut microbiota. (B) Distributions of the samples from non-CAD control individuals and CAD patients in each cluster. Chi-squared test was used to compare the three clusters. (C) Relative abundance of Bacteroides spp. Data are presented as the medians and interquartile ranges (25th–75th percentiles). (D) Relative abundance of Bacteroides vulgatus and Bacteroides dorei. Data are presented as medians and interquartile ranges (25th–75th percentiles). *p<0.05, **p<0.01.

Fig. 1. Gut microbial characteristics of participants with or without coronary artery disease (CAD)

The exception of the lipid profiles. As patients with CAD were required to reduce their plasma LDL levels for secondary prevention, they all were prescribed statins. The groups did not differ in terms of the ratio of medications used for hypertension and diabetes mellitus.

To analyze the study participants’ gut microbial profiles, the participant samples were grouped into three clusters at the genus level, as described previously (Fig. 1A)\(^\text{38}\). Cluster 1 was characterized by a high abundance of Bacteroides spp., cluster 2 was characterized by a high abundance of Prevotella spp., and cluster 3 was characterized by a high abundance of other bacterial species. The enterotype of the samples from patients with CAD differed significantly from that of non-CAD control individuals, and samples of patients with CAD were less likely to be categorized as enterotype 1 (Fig. 1B). The mean Firmicutes-to-Bacteroidetes ratio in the fecal samples from patients with CAD (2.823±1.145) was significantly higher than that from non-CAD control individuals (1.51±1.90) (p=0.0062). The CAD fecal samples contained a significantly lower mean abundance of Bacteroides spp. (12.40%±8.96%) than non-CAD fecal samples (34.87%±19.41%) (p=0.0048) (Fig. 1C). Supplementary Fig. 2 illustrates the gut microbial analyses. CAD fecal samples contained a significantly lower level of B. vulgatus and B. dorei (3.96±3.39%) than did non-CAD fecal samples (16.00±17.45%) (p=0.043) (Fig. 1D).
Impact of RS on Fecal Bacterial Cultures from the Gut Microbiota

RS did not significantly alter the numbers of total bacteria in non-CAD fecal culture (without RS: $7.55 \pm 2.59 \times 10^{10}$ copies/mL; with RS: $7.96 \pm 2.10 \times 10^{10}$ copies/mL, $p=0.66$) or in CAD fecal culture (without RS: $7.06 \pm 2.73 \times 10^{10}$ copies/mL; with RS: $8.92 \pm 4.27 \times 10^{10}$ copies/mL, $p=0.32$). The numbers of OTUs in non-CAD control fecal cultures and CAD fecal cultures that had and had not been fermented with RS were similar (Supplemental Fig. 3A, B). There were no differences between the cultures of non-CAD or CAD fecal samples that did or did not contain RS in terms of the Shannon–Wiener index and Simpson index (Supplementary Fig. 3A, Supplementary Fig. 3B).

RS did not alter the relative abundance of Bacteroidetes in the cultures of non-CAD fecal samples...
1.07 ± 1.08 × 10^10 copies/mL, p = 0.38), but some cultures showed increases in the abundance of B. vulgatus and B. dorei (Fig. 3C). RS significantly increased the absolute numbers of B. vulgatus and B. dorei in CAD fecal cultures (without RS: 2.67 ± 4.38 × 10^9 copies/mL; with RS: 6.08 ± 1.21 × 10^9 copies/mL, p = 0.019) (Fig. 3C). The absolute numbers of B. vulgatus and B. dorei declined in a few samples (Fig. 3C).

**Impact of RS on SCFA Production**

To elucidate the impact of RS on SCFA production, we measured the SCFA levels after fermentation with or without RS for 30 h. RS did not significantly change the acetate or propionate levels in both non-CAD and CAD fecal samples (Fig. 4A, Fig. 4B). However, the presence of RS was associated with a relative or significant increase in butyrate production in both non-CAD and CAD fecal cultures (Fig. 4B).
study using the KUHIMM, which appears to be able to simulate the human gut microbiota both metagenomically and metabolically. RS, a naturally occurring edible dietary fiber that is present in and added to food, is reported to significantly increase the relative abundance of bacteria of the phylum *Bacteroidetes* in mice. We chose RS as a supplement, and investigated its effect on the abundance of *B. vulgatus* and *B. dorei* by using quantitative PCR. The multi vessels in the KUHIMM are smaller than other *in vitro* models. The KUHIMM is capable of reproducing the number and diversity of microbiota species at the same level as observed in human fecal samples. Although the KUHIMM can replicate a healthy human gut microbiota and maintain its diversity, we have never tried to ferment the gut microbiota of CAD patients. Our results indicated that 30-h fermentation in the KUHIMM did not lead to significant changes in the numbers of OTUs or the *H*-diversities in CAD and non-CAD fecal cultures. In addition, 30-h fermentation in the KUHIMM showed decreased relative abundance of *B. vulgatus* and *B. dorei* in the CAD fecal cultures compared non-CAD control fecal cultures. These results suggest that the KUHIMM could be used to simulate gut microbiota for prebiotic evaluation in patients with CAD.

Contrary to our expectations, our results showed that RS did not uniformly alter the abundance of bacteria of the phylum *Bacteroidetes* and of the genus *Bacteroides*.

SCFA production profiles differed among the individuals.

**Discussion**

Increasing evidence has been supporting a robust relationship between the gut microbiota and the incidence of cardiovascular diseases. Our previous translational research findings have shown that reductions in the abundance of *B. vulgatus* and *B. dorei* in the gut microbiota contribute to the incidence of CAD. These results suggest that increasing the abundance of *B. vulgatus* and *B. dorei* within the gut microbiota may prevent and treat CAD.

Several clinical studies have demonstrated the beneficial effects of dietary fiber on glycemic control, cholesterol level control, blood pressure regulation, and body weight control. Following improvements in the management of these coronary risk factors, dietary fiber can prevent the future incidence of CAD. Although several potential mechanisms have been proposed regarding the role of RS on gut microbiota, there have been no interventional clinical trials that have investigated its role on the gut microbiota of patients with CAD. This is the first study to investigate the effect of dietary fibers on fecal sample cultures of patients with CAD and non-CAD individuals with coronary risk factors. To overcome ethical and funding considerations, we performed this *in vitro* study using the KUHIMM, which appears to be able to simulate the human gut microbiota both metagenomically and metabolically. RS, a naturally occurring edible dietary fiber that is present in and added to food, is reported to significantly increase the relative abundance of bacteria of the phylum *Bacteroidetes* in mice. We chose RS as a supplement, and investigated its effect on the abundance of *B. vulgatus* and *B. dorei* by using quantitative PCR.

The multi vessels in the KUHIMM are smaller than other *in vitro* models. The KUHIMM is capable of reproducing the number and diversity of microbiota species at the same level as observed in human fecal samples. Although the KUHIMM can replicate a healthy human gut microbiota and maintain its diversity, we have never tried to ferment the gut microbiota of CAD patients. Our results indicated that 30-h fermentation in the KUHIMM did not lead to significant changes in the numbers of OTUs or the *H*-diversities in CAD and non-CAD fecal cultures. In addition, 30-h fermentation in the KUHIMM showed decreased relative abundance of *B. vulgatus* and *B. dorei* in the CAD fecal cultures compared non-CAD control fecal cultures. These results suggest that the KUHIMM could be used to simulate gut microbiota for prebiotic evaluation in patients with CAD. Contrary to our expectations, our results showed that RS did not uniformly alter the abundance of bacteria of the phylum *Bacteroidetes* and of the genus *Bacteroides*.

**Fig. 4.** Changes in short-chain fatty acid production after 30-h fermentation with resistant starch (RS) in the Kobe University Human Intestinal Microbiota Model (KUHIMM)

Fecal samples from (A) non-coronary artery disease (CAD) control subjects and (B) CAD patients were co-cultured with RS in the KUHIMM, and changes in the production of short-chain fatty acids after 30 h of fermentation were analyzed. The changes are presented as ratios relative to the without-RS (Culture) group. The data presented are the medians and interquartile ranges (25th–75th percentile). *p* < 0.05.
in non-CAD and CAD fecal sample cultures in the KUHIMM. Although we found that RS could significantly increase the abundance of *B. vulgatus* and *B. dorei* in CAD fecal sample cultures, this effect varied among patients. Fecal sample analysis determined that most CAD fecal samples could be categorized as enterotypes 2 or 3 and that they had a lower abundance of *B. vulgatus* and *B. dorei*, suggesting that RS supplementation could be more beneficial for patients with CAD than for control individuals without CAD. The heterogeneous responses to RS could be explained by the complexity of the gut microbial ecosystem. Functional differences cause the intestinal microbiota to either compete or cooperate for nutritional substrates, resulting in the presence of a dynamic microbial network. These complex networks within individuals generate different RS degradation potentials, and induce the formation of gut microbiota with different microbial profiles. Although the recommended daily adult intakes of dietary fiber range from 30 to 35 g for men and from 25 to 32 g for women, the mean daily intakes of dietary fiber within the Japanese general population are about 18.8 ± 10.2 g for men and 18.0 ± 8.0 g for women. The results from this study could be used to promote food education among patients with CAD who are RS responders.

We demonstrated that RS supplementation increased butyrate production in CAD fecal sample cultures, suggesting that the gut microbial metabolites could be altered by RS assimilation. SCFAs are used as energy sources by host cells and the gut microbiota, influence the physiology of the colon, help shape the gut environment, and function as signaling molecules to regulate host metabolism and immune responses. RS supplementation increases fecal butyrate concentrations in healthy young adults. Moreover, butyrate is the predominant fermentation product from RS. In this study, we demonstrated, for the first time, that RS could increase butyrate production in CAD fecal sample cultures in the KUHIMM. Butyrate supports the function of the mucosal barrier by stimulating intestinal mucous production, and it induces the differentiation of colonic regulatory T cells in mice. The findings from animal experiments have shown that a butyrate-supplemented diet suppresses atherosclerotic plaque formation in apolipoprotein E-knockout mice via reductions in the expression of chemokines and adhesion molecules at the site of the lesion, which were followed by lower levels of macrophage migration. Furthermore, peritoneal macrophages from butyrate-treated mice exhibited lower levels of reactive oxygen species generation. On the contrary, bacteria of the phylum *Bacteroidetes* produce propionate. RS did not increase propionate production nor did it increase the relative abundance of *Bacteroidetes* bacteria. Although few studies have shown that SCFAs protect against atherosclerosis, this evidence offers an insight into the pathophysiology of atherosclerosis as a chronic inflammatory diseases, and we could expect the development of novel therapeutic approaches that prevent CAD progression by modulating the gut microbiota through dietary fiber consumption.

The present study had several limitations, which should be considered when interpreting the results. First, this was a study with a relatively small number of Japanese patients. Large cohort studies are needed to ascertain these observations. Second, we mainly focused on the effect of RS on the changes in the abundance of *B. vulgatus* and *B. dorei*, and SCFA production in this study. Other important changes might exist, warranting future research.

**Conclusion**

We have, for the first time, demonstrated heterogeneous responses of the gut microbiota and SCFA production following RS supplementation of CAD and non-CAD fecal samples cultures in the KUHIMM. The KUHIMM may be useful for preclinical testing of the effects of RS on the cultures of gut microbiota from patients’ fecal samples and their metabolites. Our results pave the way for further investigations on gut microbial response to RS supplementation and CAD prevention and management.

**Conflict of Interest**

The authors declare they have no conflicts of interest.

**Acknowledgments**

We thank the study subjects and are grateful to the medical staff for their cooperation in collecting the fecal samples. We thank Ayami Fujino, Yasuko Koura, Shoko Sakai, and Hiromi Nishiki for their excellent technical support.

**Notice of Grant Support**

This work was supported by the Japan Milk Academic Alliance, Japan Innovative Bioproduction Kobe from the Ministry of Education, Culture, Sports and Technology, and PRIME from the Japan Agency for Medical Research and Development (18069370).
References

1) Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, and JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207

2) Suwa S, Ogita M, Miyachi K, Sonoda T, Konishi H, Tsuboi S, Wada H, Naito R, Dohi T, Kasai T, Okazaki S, Isoda K, Daida H: Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. J Atheroscler Thromb, 2017; 24: 1125-1131

3) Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Schmid JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, and Hazen SL: Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature, 2011; 472: 57-63

4) 'Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, and Hazen SL: Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med, 2013; 368: 1575-1584

5) Jonsson AL and Bäckhed F: Role of gut microbiota in atherosclerosis. Nat Rev Cardiol, 2017; 14: 79-87

6) Ji E, Xia H, Zhong SL, Feng Q, Li S, Liang S, Zhong H, Liu Z, Gao Y, Zhao H, Zhang D, Su Z, Fang Z, Lan Z, Li J, Xiao L, Li J, Li R, Li X, Li F, Ren H, Huang Y, Peng Y, Li G, Wen B, Dong B, Chen JY, Geng QS, Zhang ZW, Yang H, Wang J, Wang J, Zhang X, Madsen L, Brix S, Ning G, Xu X, Liu X, Hou Y, Jia H, He K, and Kristiansen K: The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun, 2017; 8: 845. doi: 10.1038/s41467-017-00900-1

7) Yoshida N, Yamashita T, and Hirata KI: Gut microbiome and cardiovascular diseases. Diseases, 2018; 6: 56. doi:10.3390/diseases6030056

8) Emoto T, Yamashita T, Kobayashi T, Sasaki N, Hirota Y, Hayashi T, So A, Kasahara K, Yodoi K, Matsumoto T, Mizoguchi T, Ogawa W, and Hirata KI: Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease. Heart Vessels, 2017; 32: 39-46

9) Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A, Kasahara K, Yodoi K, Matsumoto T, Mizoguchi T, Ogawa W, and Hirata K: Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb, 2016; 23: 908-921

10) Karlsson FH, Fåk F, Noookaew I, Tremaroli V, Fagerberg B, Petranovic D, Bäckhed F, and Nielsen J: Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun, 2012; 3: 1245. doi: 10.1038/ncomms2266

11) Yin J, Liao SX, He Y, Wang S, Xia GH, Liu FT, Zhu JJ, You C, Chen Q, Zhou L, Pan SY, and Zhou HW: Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack. J Am Heart Assoc, 2015; 4. doi: 10.1161/JAHA.115.002699

12) Yoshida N, Emoto T, Yamashita T, Watanabe H, Hayashi T, Tabata T, Hoshi N, Hatano N, Ozawa G, Sasaki N, Mizoguchi T, Amin HZ, Hirota Y, Ogawa W, Yamada T, and Hirata KI: Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation, 2018; 138: 2486-2498

13) Yamashita T, Emoto T, Sasaki N, and Hirata KI: Gut microbiota and coronary artery disease. Int Heart J, 2016; 57: 663-671

14) Yamashita T: Intestinal Immunity and Gut Microbiota in Atherogenesis. J Atheroscler Thromb, 2017; 24: 110-119.

15) Flint HJ, Scott KP, Louis P, and Duncan SH: The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol, 2012; 9: 577-589

16) Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, Almeida M, Quinquis B, Levenez F, Galleron N, Gougis S, Rizkalla S, Batto JM, Renault P, ANR MicroObes consortium, Dore J, Zucker JD, Clément K, and Ehrlich SD: Dietary intervention impact on gut microbial gene richness. Nature, 2013; 500: 585-588

17) Sonnenburg ED, Smits SA, Tikhonov M, Higginsbottom SK, and Wingreen NS, Sonnenburg JL: Diet-induced extinction in the gut microbiota compounds over generations. Nature, 2016; 529: 212-215

18) Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H, Xue X, Lu C, Ma J, Yu L, Xu C, Ren Z, Xu Y, Xu S, Shen H, Zhu X, Shi Y, Shen Q, Dong W, Liu R, Ling Y, Zeng Y, Wang X, Zhang Q, Wang J, Wang L, Wu Y, Zeng B, Wei H, Zhang M, Peng Y, and Zhang C: Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science, 2018; 359: 1151-1156

19) De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, and Lionetti P: Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A, 2010; 107: 14691-14696

20) Upadhyaya B, McCormack L, Fardin-Kia AR, Juenemann A, Kevaney J: Diet and 20-year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. N Engl J Med, 1985; 312: 811-818

21) Kushi LH, Lew RA, Stare FJ, Ellison CR, el Lozy M, Bourke G, Daly L, Graham I, Hickey N, Mulcahy R, and Keavaney J: Diet and 20-year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. N Engl J Med, 1985; 312: 811-818

22) Picketen P, Rimm EB, Korhonen P, Hartman AM, Willett WC, Albanes D, and Virtamo J: Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Circulation, 1996; 94: 2720-2727

23) Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, and Willett WC: Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA, 1996; 275: 447-451

24) Sawicki CM, Livingston KA, Ohin M, Roberts SB,
Chung M, and McKeown NM: Dietary fiber and the human gut microbiota: application of evidence mapping methodology. Nutrients, 2017; 9: E125. doi: 10.3390/nu9020125

25) Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, and Rudensky AY: Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature, 2013; 504: 451-455

26) Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Tato M, Takahashi M, Fukuda NN, Murakami S, Miyauuchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, and Ohno H: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 2013; 504: 446-450

27) Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauuchi S, Kobayashi M, Hirasawa A, and Tsujimoto G: Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A, 2011; 108: 8303-8305

28) Takagi R, Sasaki K, Sasaki D, Fukuda I, Tanaka K, Yoshida K, Kondo A, and Osawa R: A single-batch fermentation system to simulate human colonic microbiota for high-throughput evaluation of prebiotics. PLoS One, 2016; 11: e0160533. doi: 10.1371/journal.pone.0160533.

29) Sasaki K, Sasaki D, Okai N, Tanaka K, Nomoto R, Fukuda I, Yoshida KI, Kondo A, and Osawa R: Taurine does not affect the composition, diversity, or metabolism of human colonic microbiota simulated in a single-batch fermentation system. PLoS One, 2017; 12: e0180991. doi: 10.1371/journal.pone.0180991

30) Sasaki D, Sasaki K, Ikuta N, Yasuda T, Fukuda I, Kondo A, and Osawa R: Low amounts of dietary fibre increase in vitro production of short-chain fatty acids without changing human colonic microbiota structure. Scirep, 2018; 8: 435. doi: 10.1038/s41598-017-18877-8

31) Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A, Mackay CR, and Kaye DM: High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation, 2017; 135: 964-977

32) Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Knop M, Yilmaz P, Coursier E, and unwgkem J: Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res, 2013; 41: e1. doi: 10.1093/nar/gks808

33) Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JL, Huttles GA, Kelley ST, Knights D, Kovacik JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, and Knight R: QIIME allows analysis of high-throughput community sequencing data. Nat Methods, 2010; 7: 335-336

34) Edgar RC: Search and clustering orders of magnitude faster than BLAST. Bioinformatics, 2010; 26: 2460-2461

35) Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, Ciulla D, Tabbaa D, Highlander SK, Sodergren E, Methé B, DeSantis TZ, Human Microbiome Consortium, Peterson JF, Knight R, and Birren BW: Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res, 2011; 21: 494-504

36) Wang Q, Garrity GM, Tiedje JM, and Cole JR: Naïve Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol, 2007; 73: 5261-5267

37) Odamaki T, Xiao JZ, Sakamoto M, Kondo S, Yashima T, Iwatsuki K, Togashi H, Enomoto T, and Benno Y: Distribution of different species of the Bacteroides fragilis group in individuals with Japanese cedar pollinosis. Appl Environ Microbiol, 2008; 74: 6814-6817

38) Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandez GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Sirois M, Torrents D, Ugarte E, Zeeuendal E, Wang J, Guarnier F, Pedersen O, de Vos WM, Brunak S, Doré J: MetaHIT Consortium, Antolín M, Artigane-F Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cullotone A, Delorme C, Denariaz G, Dervyn R, Foresen KT, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Molinard R, M‘rini C, Muller J, Oazerer R, Parkhill J, Renault P, Risco-Moño N, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Z, Yeller G, Weissenbach J, Ehrlich SD, and Bork P: Enterotypes of the human gut microbiome. Nature, 2011; 473: 174-180

39) Chandel M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, and Brinkley LJ: Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med, 2000; 342: 1392-1398

40) Williams CF, Walton GE, Jiang L, Plummer S, Tominaga M, Hori S, Ohara O, Dervyn R, Foerster NU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M‘rini C, Muller J, O傲reer R, Parkhill J, Renault P, Risco-Moño N, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Z, Yeller G, Weissenbach J, Ehrlich SD, and Bork P: Enterotypes of the human gut microbiome. Nature, 2011; 473: 174-180
45) Venkataraman A, Sieber JR, Schmidt AW, Waldron C, Theis KR, and Schmidt TM: Variable responses of human microbiomes to dietary supplementation with resistant starch. Microbiome, 2016; 4: 33. doi: 10.1186/s40168-016-0178-x

46) Herrmann E, Young W, Reichert-Grimm V, Weis S, Riedel C, Rosendale D, Stoklosinski H, Hunt M, and Egert M: In vivo assessment of resistant starch degradation by the caecal microbiota of mice using RNA-based stable isotope probing-a proof-of-principle study. Nutrients, 2018; 10: E179. doi:10.3390/nu10020179

47) Aguilar EC, Leonel AJ, Teixeira LG, Silva AR, Silva JF, Pelaez JM, Capettini LS, Lemos VS, Santos RA, and Alvarez-Leite JI: Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFkB activation. Nutr Metab Cardiovasc Dis, 2014; 24: 606-613

48) Aguilar EC, Santos LC, Leonel AJ, de Oliveira JS, Santos EA, Navia-Pelaez JM, da Silva JF, Mendes BP, Capettini LS, Teixeira LG, Lemos VS, and Alvarez-Leite J: Oral butyrate reduces oxidative stress in atherosclerotic lesion sites by a mechanism involving NADPH oxidase down-regulation in endothelial cells. J Nutr Biochem, 2016; 34: 99-105

49) den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, and Bakker BM: The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res, 2013; 54: 2325-2340
Supplementary Fig. 1. Kobe University’s Human Intestinal Microbiota Model is a single-batch fermentation system composed of eight parallel and independent anaerobic culturing vessels.

Supplementary Fig. 2. Gut microbiota of patients with or without coronary artery disease (CAD)

Feces were collected from 10 non-CAD control subjects and 11 CAD patients. The V3–V4 region of the bacterial 16S ribosomal ribonucleic acid was sequenced. The relative abundance of the microbial genera is shown. Genera with a lower abundance (<1.0\%) and lower levels of similarity (<97\%) were classified as Others and Uncultured bacteria, respectively.
Supplementary Fig. 3. Bacterial 16S ribosomal ribonucleic acid gene sequencing data and \( \alpha \)-diversity values after incubation with resistant starch (RS) in Kobe University's Human Intestinal Microbiota Model. The operational taxonomic unit numbers, Shannon–Wiener index, and Simpson index for each culture incubated with or without RS are shown. (A) Non-coronary artery disease (CAD) control subjects. (B) CAD patients.
Supplementary Fig. 4. Genus-level compositional view of the bacteria after fermentation for 30 h
Samples were obtained from each vessel of Kobe University’s Human Intestinal Microbiota Model (KUHIMM) after 30 h of fermentation without resistant starch (RS) and with RS. The bacterial 16S ribosomal ribonucleic acid gene sequences were analyzed, and the relative abundance at the genus level are presented. Genera with a lower abundance (<1.0%) and lower levels of similarity (<97%) were classified as Others and Uncultured Bacteria, respectively.